ArticleAMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science2026
Adaptive Integration of Incomplete Multimodal 3D Neuroimaging for Alzheimer's Prediction and Biomarker Discovery.
Article in AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) diagnosis requires analysis of diverse data types to capture the heterogeneous factors underlying its development and progression. Magnetic resonance imaging (MRI) and positron emission tomography (PET) noninvasively measure brain structure and neuronal activity, respectively, and can serve as early indicators of AD onset and future progression. We propose V3D-MMoE, an interpretable framework to adaptively integrate incomplete multimodal 3D neuroimaging for AD diagnosis prediction and biomarker discovery. It goes beyond prior approaches by leveraging (1) a sparse mixture-of-experts formulation to account for variation in the importance of different modality combinations, (2) modality alignment to enhance cross-modal learning, and (3) cross-encoders to dynamically handle missing modalities. When applied to MRI and PET scans to predict two-year AD diagnosis, V3D-MMoE outperformed state-of-the-art multimodal 3D neuroimaging methods. Interpretability analyses revealed subject-specific MRI and PET biomarkers consistent with the known biology of AD. Ablation experiments demonstrated the benefit of leveraging multimodal neuroimaging.
Identifiers
42317807PMC13274276What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.